TY  - BOOK
AU  - Davis Lori 
AU  - Casselbury Mary Beth, Wilson Sharon
TI  - Checkpoint inhibitor therapy: Immune-related adverse event management
SN  - 0360-4039
KW  - Checkpoint inhibitor therapy, immune-related adverse events (irAEs), immune checkpoint inhibitors (ICIs), immunotherapy, oncology
N1  - Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities
ER  -